This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (6)  • Contact me when this article is cited  Related Content  • Similar articles in this journal

Arch Intern Med. 2001;161:1678.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Recently, Mundy et al¹ indicated that some statins (3-hydroxy-3-methylglutaryl coenzyme A [HMG Co-A] reductase inhibitors) have a potent stimulatory effect on bone formation in vitro and in experimental animals. However, Wada et al² found that bone mineral density (BMD) did not increase, but rather unexpectedly decreased in subjects with type 2 diabetes mellitus who are receiving therapy with statins compared with those who are not.

Fisher et al³ have indicated that geranylgeraniol, an intermediate product in the mevalonate pathway, prevents inhibition of osteoclast formation and function. Therefore, we speculate that an augmented mevalonate pathway may reduce BMD. In our study comprising 783 consecutive Japanese patients visiting our clinic since 1994, we examined the relationship between hypercholesterolemia and reduced BMD in type 2 diabetes mellitus. We measured BMD of the lumbar spine (L2-L4) in all subjects, as previously described.^{1, 4-5} We defined osteopenia and osteoporosis according to World Health Organization (WHO) criteria . . . [Full Text of this Article]

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Plasma Low-Density Lipoprotein Cholesterol and Bone Mass Densitometry in Postmenopausal Women
Poli et al.
Obstet Gynecol 2003;102:922-926.
ABSTRACT | FULL TEXT